Frequently asked questions about CLEANUS
Question: For which clinical indications is the CLEANUS ureteral stent indicated or primarily advantageous?
Answer: The CLEANUS stent is designed to optimize the drainage of the upper urinary tract across a broad range of clinical scenarios, offering specific benefits in both short-term and long-term indwelling applications.
- Primary Clinical Indications:
- Ureterolithiasis: Managing stone-related obstructions where stent-related complications are a concern.
- Extrinsic Ureteral Obstruction: Providing reliable drainage in cases of compression from external masses or anatomical structures.
- Post-Endourological Procedures: Ensuring consistent urinary patency and reducing infection risk following complex endourological interventions.
- Clinical Value: By minimizing encrustation and biofilm-related complications, the technology is particularly advantageous in high-risk patients or those requiring extended drainage periods.
Question: What are the clinical advantages of the CLEANUS stent for long-term ureteral drainage?
Answer: The CLEANUS stent is specifically designed to mitigate the risks associated with long-term indwelling duration, most notably crystalline encrustation.
- Superior Encrustation Resistance: By significantly reducing the formation of mineral deposits, CLEANUS maintains stent patency over extended periods.
- Performance Under High-Risk Conditions: Clinical study data demonstrates that the efficacy of the CLEANUS coating is directly correlated with the degree of encrustation burden; the higher the patient's risk profile, the more pronounced the protective effect becomes.
- Improved Patient Outcomes: By preventing encrustation-related emergencies, CLEANUS reduces the need for premature stent exchanges, lowers complication rates, and enhances the overall patient quality of life.
Question: What are the clinical benefits of the CLEANUS stent for short-term ureteral drainage?
Answer: Clinical studies demonstrate that the CLEANUS stent provides significant therapeutic advantages over conventional stents even during short-term indwelling periods (e.g., 7 days). Key clinical outcomes include:
- Symptom Reduction: Documented decrease in patient-reported symptoms, including reduced nocturia and lower pain levels.
- Antibiotic Stewardship: Significant reduction in the requirement for post-operative antibiotic therapy due to lower infection risk.
- Enhanced Patient Quality of Life (QoL): Improved patient comfort and overall well-being during the treatment period compared to standard-of-care devices.
- Efficacy Timeline: These clinical benefits are observed and statistically significant within an indwelling period as short as 7 days.
Question: Does the CLEANUS technology involve drug elution or the release of active substances?
Answer: No, the CLEANUS technology is entirely non-pharmacological. It does not involve the elution or systemic release of any substances.
- Non-Active Mechanism: The coating does not utilize pharmacologically, immunologically, or metabolically active agents, distinguishing it from drug-eluting stents.
- Stable Surface Modification: The physicochemical coating is covalently bonded to the stent surface.
- Long-Term Stability: The covalent bond is highly stable under physiological conditions (pH 6.0, core body temperature), with a calculated chemical half-life of approximately 400 to 500 years. This ensures the coating remains integrated with the device throughout the entire indwelling duration.
Question: Does the CLEANUS coating alter the mechanical or physical properties of the underlying ureteral stent?
Answer: No, the CLEANUS coating does not alter the baseline dimensions or mechanical properties of the ureteral stent.
- Sub-Micrometer thickness: The coating thickness is in the sub-micrometer range, remaining well below standard manufacturing tolerances, ensuring the stent's original physical integrity is maintained.
- Surface Characteristics: The application results in a slight shift in surface energy toward increased hydrophilicity. This supports smooth insertion and handling characteristics while ensuring the device performs according to its original design specifications.
Question: Which base materials are compatible with the CLEANUS technology?
Answer: The CLEANUS technology is engineered for high material versatility, allowing it to be applied to a wide range of substrates without compromising their base physical and mechanical properties.
- Supported Polymers: The coating is compatible with, but not limited to, polyurethane (PU), polyethylene (PE), and silicone.
- Metallic Substrates: The technology is also applicable to various medical-grade metals frequently utilized in urological devices, offering a consistent surface modification across diverse device platforms.
- Performance Consistency: This versatility allows manufacturers to leverage the specific mechanical advantages of their existing base materials while integrating the enhanced surface properties provided by the CLEANUS technology.